Ready to Trade? Pre-Market Insights, Top Gainers & Crucial FDA News

Don’t want emails from us anymore? Click here to unsubscribe

Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

  • Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

  • Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

  • Top Pre-Market Movers: Identify early winners poised for a strong market opening.

  • Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

  • FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.


Sponsored

Boost your portfolio in 2024 with this ultra low-priced copper stock

Small-cap copper stocks have a history of moving up in a copper bull market. Driven by the clean energy transition, it's happening again now.

Check out this 10-cent copper stock with nearly 1 billion pounds Cu confirmed in mining-friendly Canada.

Check out our free report here. 

Happening Today

✓ 09:00 AM ET – FOMC Member Bowman Speaks

✓ 10:00 AM ET – Michigan 1-Year Inflation Expectations (May)

✓ 10:00 AM ET – Michigan 5-Year Inflation Expectations (May)

✓ 10:00 AM ET – Michigan Consumer Expectations (May)

✓ 10:00 AM ET – Michigan Consumer Sentiment (May)

✓ 12:00 PM ET – WASDE Report

PREMARKET SNAPSHOT 📈

Stock futures are pointing to a flat open with the Dow Jones leading the way with a modest gain of nearly 1%.

S&P500

$5214.08

⬆️ 0.51%

Dow

$39387.76

⬆️ 0.84%

NASDAQ

$18113.463

⬆️ -0.16% 

SECTOR SNAPSHOT 

Most sectors edged up in today's mixed market; Real Estate surged 2.31%, while Tech dipped 0.25%.

NAME

PRICE

%CHANGE

Consumer Discretionary

1,464.58

+0.69% 🟢

Consumer Staples

823.06

+0.76% 🟢

Energy

720.42

+1.36% 🟢

Financials

692.13

+0.69% 🟢

Health Care

1,668.56

+0.79% 🟢

Industrials

1,062.00

+0.92% 🟢

Materials

577.47

+1.08% 🟢

Real Estate

237.73

+2.31% 🟢

Information Technology

3,769.40

-0.25% 🔴

Communication Services

292.77

+0.38% 🟢

Utilities

361.95

+1.52% 🟢


Sponsored

Must Read Report BEFORE Investing in AI

Elon Musk calls AI "the most disruptive force in history." With the potential to disrupt entire industries, experts believe the AI explosion will alter the course of the economy. While Silicon Valley bankrolls projects that expand AI technology, investors are flocking to companies with innovative AI platforms.

One small AI company is at the forefront of it all - get the full story here

Unusual Volume

📈 Reborn Coffee Inc (REBN) jumped 84.39% to $3.19 on a whopping 109.96 million shares traded after it announced a significant expansion into the China market through a strategic Master License Agreement with IAID Co., Ltd.

📈 Investors went wild, sending Fuelcell Energy Inc (FCEL) stock declining -3.52% to $0.76 on a massive volume of 84.39 million shares.

📈 Abnormal activity shook Uber Technologies Inc (UBER), pushing it down -5.72% to $66.40 on a whopping 84.22 million shares traded after announcing results for first quarter 2024.

📈 Safe and Green Development Corp (SGD) stock recently closed 58.81% upper at $0.62 on substantial volume of 70.08 million shares. This unusual activity came after the company announced its partnership with Affiliated Services Group (ASG) to offer mortgage banking related services on its innovative Xene platform across 49 states in the U.S.

📈 Luminar Technologies Inc (LAZR) increase by 18.79% in a single trading session, with abnormally high trading volume of 61.55 million shares. The company provided its quarterly business update and financial results for the first quarter of 2024.


Sponsored

Bank of America Analysts Say this AI Company Could Grow 400% in the Next 3 Years

Some analysts say this company's 900% growth in the last year is a "one-and-done" pop, but Bank of America analysts disagree. In fact, they say it could go 4x higher in the next 3 years.

Click Here for the Stock Bank of America Says Could Quintuple Revenues 4x Over the Next 3 Years!

Premarket Movers

Novavax, Inc. (NVAX) experiences a substantial 115.44% surge in pre-market trading after announcing a co-exclusive licensing agreement with Sanofi.

AEye, Inc. (LIDR) sees a significant 35.59% increase, reaching a pre-market price of $1.60 after announcing partnership with leading automotive electronics and vision solutions provider, LITEON.

SoundHound AI, Inc. (SOUN) demonstrates a noteworthy 14.11% surge, with a pre-market price of $5.42 after reporting 73% Q1 revenue growth to $11.6 million.

Pre Market Gainers

Pre Market Change

Pre Market Volume

NVAX

+115.44%

11.41M

LIDR

+35.59%

2.19M

GETR

+10.95%

1.08M

SOUN

+13.26%

940.11K

SRTS

+30.71%

366.18K

WISA

+8.22%

296.11K

CLSK

+5.06%

167.72K

ZIM

+3.33%

86.51K

LAZR

+3.55%

65.05K

CBAT

+6.31%

60.17K


Sponsored

How to collect FAT dividend checks in the AI boom

Investing legend Tim Melvin reveals the #1 dividend stock for the AI Boom.

This stock is paying an ultra-fat dividend up to 12%!

Because according to the New York Times, "AI could soon need as much electricity as an entire COUNTRY." And this stock is perfectly positioned to get rich in an energy starved economy.

But you MUST buy before May 9th.

Click HERE to claim your FREE report.

Important FDA 

Recently Announced

April 29th, 2024, marks a pivotal moment in Pfizer Inc.'s (PFE) journey as the FDA grants full approval for TIVDAK, a breakthrough in treating recurrent or metastatic cervical cancer. This decision highlights Tivdak's efficacy and safety, providing a beacon of hope for patients post-initial therapy, offering potential for improved outcomes.

On April 30th, 2024, Neurocrine Biosciences Inc. (NBIX) achieves a significant milestone with the FDA's approval of INGREZZA's oral granules formulation. This innovative drug delivery system signals a new chapter in managing tardive dyskinesia and chorea linked to Huntington's disease.

April 30th, 2024, emerges as a historic date for X4 Pharmaceuticals, Inc (XFOR), as the FDA greenlights Mavorixafor, bringing hope to individuals aged 12 and older grappling with WHIM syndrome. This approval not only confirms Mavorixafor's effectiveness and safety but also marks a crucial advancement in treating this rare and challenging condition.

Upcoming Announcements

The anticipation surrounding Moderna's (MRNA) pivotal moment on May 12th, 2024, is palpable. As the FDA's decision on mRNA-1345, their innovative RSV vaccine, looms closer, stakeholders are holding their breath. If the outcome aligns with expectations, it could signify a significant advancement in the fight against respiratory syncytial virus, promising a safer and more efficient defense against this widespread threat.

May 13th, 2024, holds immense significance for Dynavax Technologies Corp. (DVAX) as they await the FDA's ruling on HEPLISAV-B, a vaccine with potential expanded usage among adults undergoing hemodialysis. With anticipation mounting among stakeholders as the date approaches, there's a sense of anticipation for a potential breakthrough that could elevate the standard of care for this vulnerable patient group.

On May 14th, 2024, attention shifts to Ascendis Pharma A/S (ASND) as they await the FDA's decision on TransCon PTH. With the resubmitted NDA targeting the urgent needs of adult patients grappling with hypoparathyroidism, the outcome carries significant weight. A favorable verdict could signal a new chapter in treatment options, providing hope and relief for those burdened by this challenging condition.

🎁 Looking for More? Check out these complementary newsletters for diverse perspectives:

Sponsored
The Money ManiacMaster your money in just 5 minutes every Friday

Happy investing,

Maeve Grace
Editor In Chief
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.

Join the conversation

or to participate.